Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Gliosarcoma × Basiliximab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1 CNS 1

Conditions

Hodgkin Disease 4 Precursor Cell Lymphoblastic Leukemia-Lymphoma 3 Leukemia, Myeloid, Acute 3 Primary Myelofibrosis 2 Multiple Myeloma 2 Lymphoma, Non-Hodgkin 2 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2 Leukemia, Lymphocytic, Chronic, B-Cell 2 Glioblastoma 2 Anemia, Refractory, with Excess of Blasts 2 Neoplasms 1 Myelodysplastic Syndromes 1 Lymphoma, Mantle-Cell 1 Lymphoma, Extranodal NK-T-Cell 1 Hemoglobinuria, Paroxysmal 1 Hematologic Neoplasms 1 Gliosarcoma 1 Brain Neoplasms 1 Anemia, Aplastic 1

Interventions

Temozolomide 122 Radiotherapy 81 Bevacizumab 41 Radiation 30 Carmustine 26 Irinotecan 21 Erlotinib Hydrochloride 21 Magnetic Resonance Spectroscopy 18 Chemotherapy, Adjuvant 17 Surgical Procedures, Operative 13 O(6)-benzylguanine 13 Carboplatin 13 sargramostim 12 Radiotherapy, Intensity-Modulated 11 Radiotherapy, Conformal 11 Imatinib Mesylate 9 Thalidomide 8 Drug Therapy 8 motexafin gadolinium 7 Radiosurgery 7 Procarbazine 7 Gefitinib 7 Filgrastim 7 Cyclophosphamide 7 pembrolizumab 6 cediranib 6 Vorinostat 6 Sirolimus 6 Lomustine 6 Hydroxyurea 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00626483 2021-03-09

REGULATe

Duke University

Phase 1 Completed

Brain Neoplasms, Glioblastoma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡